Market Intelligence, Preclinical Progress, and High-Purity Reagents for Retinal Degeneration & Hematologic Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FIZ1 (FLT3-Interacting Zinc finger 1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FIZ1 Recombinant Protein (Wild-Type / Mutant). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Full-length with intact Zinc Finger domain. | View FIZ1 Products |
| Gene Delivery | FIZ1 Premade Lentivirus (ORF). Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. Sequence Verified. | View FIZ1 Products |
| Benchmark Ab | Anti-FIZ1 Reference Antibody. Research-grade control for western blot, immunoprecipitation, and intracellular flow cytometry. | View FIZ1 Products |
| Validator | FIZ1 siRNA Set (3 unique sequences). For knockdown verification and downstream signaling pathway analysis. | View FIZ1 Products |
| Related Target (Retinal) | NR2E3. Nuclear receptor partner in retinal transcription complex. | View NR2E3 Products |
| Related Target (Retinal) | NRL. Master regulator of photoreceptor fate; forms co-activation complex with FIZ1. | View NRL Products |
| Related Target (Hematologic) | FLT3. Primary interacting receptor; kinase mutations drive AML resistance. | View FLT3 Products |
| Related Target (Hematologic) | STAT5A. Downstream transcription factor modulated by the FLT3-FIZ1 signaling axis. | View STAT5A Products |
| Related Target (Epigenetic) | DNMT1. Functional assay support for FIZ1-mediated methylation studies. | View DNMT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI validation (FIZ1/NR2E3/NRL or FIZ1/FLT3) | Human & Mouse full-length and Zinc Finger domain proteins, HEK293 expressed, >95% purity, Sequence Verified. Suitable for SPR, BLI, AlphaScreen. |
| Nuclear translocation & transcriptional reporter assays | FIZ1 Premade Lentivirus particles for stable cell line construction and live-cell imaging. |
| Zinc Finger proteome selectivity & off-target profiling | C2H2 domain-specific recombinant antigen with verified folding; endotoxin <1 EU/ug. Counter-screening panel available (ZNF143, ZNF384). |
| Target specificity confirmation | Predesigned siRNA included for knockdown verification and rescue experiments. |
| DNA-Binding Domain Functionality | Recombinant FIZ1 with confirmed zinc finger motifs; suitable for EMSA and fluorescence polarization assays. |
| Solubility & Aggregation Control | Multi-expression system options (E.coli/HEK293); HEK293 expressed for native mammalian post-translational modifications. |
Live FIZ1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
FIZ1 (FLT3-Interacting Zinc finger 1) is a nuclear C2H2-type zinc finger transcriptional coactivator. Its drug discovery is currently at early preclinical stages, concentrated in two major domains: retinal degenerative diseases and hematologic malignancies. In the retina, FIZ1 partners with NR2E3 and NRL to regulate photoreceptor fate, with implications for Enhanced S-Cone Syndrome and retinitis pigmentosa. In AML, FIZ1 interacts with the FLT3 receptor cytoplasmic domain, participating in aberrant signaling pathways including STAT5. The transition from traditional kinase inhibitors (e.g., Midostaurin, Gilteritinib) to targeting the FLT3 interactome represents a paradigm shift to overcome resistance. Future R&D is prioritizing protein-protein interaction inhibitors, PROTAC degraders, and AAV-mediated gene modulation strategies. No large pharma has publicly disclosed a dedicated FIZ1 program, offering a first-in-class opportunity for academic consortia and early-stage biotechs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitor | Academic Consortia, Early Biotech | FLT3-ITD AML, Relapsed/Refractory AML | AlphaScreen/TR-FRET (Need high-purity FIZ1 Zn-finger domain + FLT3 cytoplasmic domain) |
| Targeted Degradation (PROTAC) | Targeted Protein Degradation Startups | Refractory AML, MLL-Rearranged Leukemia | Ternary complex validation (Need full-length FIZ1 with intact binding surfaces) |
| Peptide/Miniprotein Inhibitor | Peptide Engineering Labs | Hematological Malignancies | SPR/BLI Kd determination (Need biotinylated FIZ1 and soluble FLT3) |
| Functional Genomics / CRISPR | CRISPR Screening Platforms | AML Subtype Stratification | Lentiviral overexpression/knockdown (Need high-titer FIZ1 virus particles) |
| Gene Therapy (AAV/FIZ1) | Academic Consortia | Retinitis Pigmentosa, Enhanced S-Cone Syndrome | Functional expression validation (Need ORF Lentivirus for in vitro transduction efficiency) |
| Intracellular Biologic (siRNA/ASO) | Preclinical Research | Oncology / Ophthalmology | Target engagement & specificity (Need quality-controlled siRNA controls) |